OCT in Rare Chorioretinal Diseases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02141308|
Recruitment Status : Recruiting
First Posted : May 19, 2014
Last Update Posted : May 2, 2019
This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and OCT angiography. Angiography is mapping of the blood vessels.
The purpose of measuring blood flow in the retina and choroid is to 1.) determine if rare diseases in these structures causes a change in blood flow compared to healthy eyes and 2.) find out if areas of changed blood flow line up with areas of damage that appear on conventional testing.
|Condition or disease|
|Retinal Artery Occlusions Polypoidal Choroidal Vasculopathy Retinal Arterial Macroaneurysm Juxtafoveal Telangiecasia Central Serous Chorioretinopathy|
Optical coherence tomography (OCT) is an imaging technology that can perform non-contact cross-sectional imaging of retinal and choroidal tissue structure in real time by measuring the intensity of reflected light. Tomographic images are generated by scanning the optical probe beam across the tissue structure of interest. OCT has become one of the most widely used imaging technologies by ophthalmologists. Its advantages include being a non-contact imaging modality, having micron-level resolution, producing a digital image that can be viewed electronically, and providing a reproducible quantitative measurement. New functional OCT including Doppler OCT and OCT angiography may allow an assessment of retinal blood flow and do away with the need for the more invasive fluorescein angiography (FA) test.
Thus, if the diagnostic data provided by functional OCT are at least equivalent or superior to those achieved by FA, patients and healthcare providers could realize a substantial benefit in utilizing this technology in the evaluation of retinal vascular disease. Even in the scenario in which an FA is not usually clinically indicated, OCT angiography may provide information over that of standard OCT and clinical examination and history, that might help clinicians better understand the etiology of the disease, and may even help inform treatment response.
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Rare Retinal and Choroidal Diseases|
|Actual Study Start Date :||May 2014|
|Estimated Primary Completion Date :||December 2022|
|Estimated Study Completion Date :||December 2022|
Rare Chorioretinal Disease
Up to 150 patients diagnosed with a rare retinal or choroidal disease will be considered and evaluated for enrollment in this study.
- Total Retinal and Choroidal Blood Flow [ Time Frame: One year ]Determination whether disease affecting the retina and/or choroid shows a change in blood flow that differs from healthy eyes.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02141308
|Contact: Denny Romfhfirstname.lastname@example.org|
|Contact: David Pooleemail@example.com|
|United States, Oregon|
|Casey Eye Institute, Oregon Health & Science University||Recruiting|
|Portland, Oregon, United States, 97239-3098|
|Contact: Denny Romfh 503-494-4351 firstname.lastname@example.org|
|Contact: David Poole 503-494-8024 email@example.com|
|Sub-Investigator: John Campbell, MD, MPH|
|Sub-Investigator: Andreas Lauer, MD|
|Sub-Investigator: Christina Flaxel, MD|
|Sub-Investigator: Thomas Hwang, MD|
|Sub-Investigator: Michael Klein, MD|
|Sub-Investigator: Steven Bailey, MD|
|Sub-Investigator: James Rosenbaum, MD|
|Sub-Investigator: Eric Suhler, MD|
|Sub-Investigator: David Huang, MD, PhD|
|Principal Investigator:||Phoebe Lin, MD, PhD||Oregon Health & Science Univeristy|